BioSpace News Archive

Tenzing Acquisition Corp., a special purpose acquisition company incorporated in the British Virgin Islands (“Tenzing”) (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation (“Reviva”) and a California-based clinical stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic,

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Veracyte, Inc. (Nasdaq: VCYT) announced today that it has promoted Richard T. Kloos, M.D., to executive medical director, overseeing Veracyte’s global medical affairs in all clinical areas addressed by the company’s expanding menu of advanced genomic tests.

Company presents robust data, including eight posters, at virtual ISA2020 in partnership with University of Tennessee Demonstrates scientific progress in the diagnosis and treatment of systemic amyloidosis through novel pan-amyloid targeting agents AT-01 and AT-02

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today appointed Yann Mazabraud as the Company’s Executive Vice President, Head of International, effective October 5, 2020

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the company will present at several upcoming virtual scientific meetings.

ClearPoint Neuro, Inc. is pleased to announce that global medical device financial executive Danilo D’Alessandro has been appointed the Company’s next Chief Financial Officer succeeding Harold A. Hurwitz who plans to retire in 2021.

Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced its financial results for the first fiscal quarter ended July 31, 2020.

MCR Labs scientist and microbiology specialist, Michael Esposito, will reframe the discussion and hopes to reshape the cannabis testing industry with a presentation that highlights differences and outlines the benefits of multiple accepted methods used to analyze cannabis products for microbiological contaminations.

PPD, Inc. announced that certain stockholders of the Company, including stockholders affiliated with Hellman & Friedman LLC and The Carlyle Group Inc., have commenced an underwritten public offering of 38,000,000 shares of the Company’s common stock pursuant to a registration statement filed with the Securities and Exchange Commission.